Both Innovative Hematology and the IHTC maintain strong partnerships in support of the bleeding and blood disorder communities at the local, state, national and international levels.
Partnering Throughout Indiana and Beyond
Advancing the research, education and treatment of rare bleeding and blood disorders would not be possible without our organization’s numerous local and global partnerships.
Local Partnerships
Hemophilia of Indiana
Hemophilia of Indiana, Inc. (HoII), is dedicated to empowering the bleeding disorder community through education and support, while advocating for access to quality care and product safety. HoII traces its beginnings to the mid-1950s when families with children with hemophilia and other bleeding disorders banded together for support and advocacy. HoII was formed as a chapter of the National Hemophilia Foundation (NHF; now National Bleeding Disorders Foundation [NBDF]) in 1963 and was incorporated as a non-profit organization in 1972.
As Indiana’s only federally designated Comprehensive Hemophilia Treatment Center (HTC) and NBDF’s only Indiana Chapter, IHTC and HoII have forged a long history of important collaborations to promote care for and education of patients with bleeding disorders.
IHTC provides financial support for several important HoII patient assistance programs including hardship support and a dental insurance program for its members.
Camp Brave Eagle
Camp Brave Eagle was originally founded by IHTC as a summer camp program for bleeding disorder children and their siblings. Today, Camp Brave Eagle enjoys active support from both IHTC and HoII, enabling 120+ children to experience a week at camp. Our staff provides onsite clinical support during the week, and HoII contributes assistance with logistics and on-site coordination.
Another collaborative effort between the two organizations includes Doug Thompson Team Leadership Camp. This camp is designed for teen boys to experience an adventure camp and learn how to advance their skills in independently managing their conditions. Our clinical staff partners with HoII staff to ensure a safe and meaningful experience.
Martin Center Sickle Cell Initiative
The Martin Center Sickle Cell Initiative (MCSCI) is committed to providing essential programs and services to benefit individuals and families affected by Sickle Cell Disease. The MCSCI also educates clients as well as community members by providing access to quality educational experiences. Innovative Hematology and the MCSCI have collaborated on various programs and services, including a statewide Sickle Cell conference, a camp for children and adolescents with Sickle Cell Disease, and various state and federal grants aimed at improving care and services for individuals with Sickle Cell Disease. Innovative Hematology also financially supports many MCSCI social service programs such as emergency hardship and travel assistance.
Camp Silver Moon
Camp Silver Moon was originally founded by our organization in partnership with the Martin Center Sickle Cell Initiative. This one-of-a-kind summer experience for children ages 7-16 with sickle cell disease is in North Webster, Indiana where campers engage in a variety of fun activities against the backdrop of an outdoor adventure camp.
Children play, create, and learn alongside their peers while making memories and friendships that will last a lifetime. Along the way, interactive lessons on healthy living will encourage them to put what they have learned about their sickle cell disease into practice and share their experiences with other children who understand their unique background.
State Partnerships
Community Health Clinic
Our organization has a long history of working with members of the Amish community to overcome barriers to care for individuals within their community affected by a bleeding disorder. From this relationship, we helped to establish the Community Dental Clinic; a local, affordable dental practice governed by representatives from the local community. Following this successful endeavor, we assisted the local community in forming a genetics clinic to address the need for local, affordable comprehensive care for individuals with other heritable disease.
IU School of Medicine
The Indiana Hemophilia and Thrombosis Center (IHTC) has a long-standing relationship with the Indiana University School of Medicine (IUSM). Dr. Anne Greist, co-founder and Co-Medical Director of IHTC, is also Associate Professor of Clinical Medicine at IUSM. Our organization provides clinical training for all IUSM adult hematology oncology fellows. This training includes rotations onsite at our clinic. We also provides financial support for the IUSM adult hematology oncology fellowship program.
Our organization has also collaborated with the IUSM on the IU Kenya Program to develop the AMPATH Hematology Program at Moi Teaching and Referral Hospital.
- Learn More About the IU School of Medicine
Indiana Department of Health
The Indiana Department of Health (IDOH) has a number of programs and services intended to benefit individuals with blood disorders. IDOH contracts with IHTC to administer the State’s Hemophilia Care and Treatment Program, which subsidizes insurance premiums for patients with Hemophilia who do not qualify for Medicaid, Medicare or employer-sponsored health insurance.
The IDOH has also contracted with our organization to perform and coordinate statewide newborn screening for Sickle Cell Disease and related red blood cell disorders since 2009. We also collaborated with the IDOH to create the Indiana Sickle Cell Consortium (ISCC); a statewide consortium of healthcare providers, community-based organizations, and other stakeholders focused on improving care and advocating for patients with sickle cell disease.
National Partnerships
MCHB
In 1975, Congress amended the Public Health Service Act to establish Comprehensive Hemophilia Diagnostic and Treatment Centers (HTC). Using a multidisciplinary team approach, HTCs provide comprehensive diagnosis, treatment, education, outreach, outcomes surveillance, research, and low cost pharmacy services to persons with hemophilia and related inherited bleeding disorders throughout the U.S. and its territories.
The Maternal and Health Bureau (MCHB) is part of the Health Resources and Services Administration (HRSA), an operating division of the U.S. Department of Health and Human Services, and has broad oversight of the HTC program. As a federally designated HTC, the IHTC receives a grant through our regional coordinating site (Hemophilia of Michigan) to provide comprehensive care and outreach for persons with bleeding and clotting disorders throughout Indiana. As part of fulfilling responsibilities under the MCHB grant, IHTC works to fulfill the goals established by MCHB in improving care and outcomes for this vulnerable patient population.
MCHB established the National Hemophilia Program Coordinating Center (NHPCC) to coordinate activities for a collaborative national infrastructure of regional hemophilia networks to promote and improve comprehensive quality care for individuals with hemophilia and related bleeding or clotting disorders such as thrombophilia. The goals of the Center are to work in conjunction with the Regional Hemophilia Network program to strengthen the capacity of the networks to improve care and to increase the evidence base on care for patients with hemophilia and related blood or clotting disorders; and track national, regional, and patient-level data to assess patient and health outcomes. Dr. Amy Shapiro, co-founder, CEO and Co-Medical Director of IHTC, also serves as Medical Director for the NHPCC.
HRSA has also established the Sickle Cell Treatment Demonstration Project and the Sickle Cell Newborn Screening and Follow-up Program; both of which utilize Innovative Hematology as a key state lead or stakeholder.
ATHN
The American Thrombosis and Hemostasis Network (ATHN) is a nonprofit organization dedicated to improving the lives of people affected by bleeding and clotting disorders. ATHN serves as a steward of the most current, extensive hemostasis and thrombosis data and analytic resources. These resources help answer difficult questions, evaluate clinical outcomes, provide evidence needed for clinical guidelines, and more.
As a founding member of the ATHN Board of Directors, Dr. Amy Shapiro, co-founder, CEO and Co-Medical Director of IHTC (now a part of Innovative Hematology), played an instrumental role in establishing the organization’s vision and inspiring all federally designated HTCs to contribute important clinical data to its national bleeding and clotting disorders database.
IHTC has provided financial support to ATHN for the purpose of establishing and enhancing its database, which in turn has enabled researchers to undertake a number of important national studies.
Hemophilia Alliance
The Hemophilia Alliance was established in 2004 as a not-for-profit organization that comprises federally funded hemophilia treatment centers (HTCs) that either have, or are seeking to have, pharmacy programs under Section 340B of the Public Health Service Act. The purpose of “the Alliance” is to promote the common interests of member HTCs. In addition to providing support through advocacy, they provide consultant expertise and organizational support.
The IHTC has been active in the Alliance since its establishment working to promote membership across the HTC network and advance its important benefits to members. The IHTC has further contributed to the Alliance through membership on its Board of Directors.
NBDF
The National Bleeding Disorders Foundation (NBDF; formerly the National Hemophilia Foundation [NHF]) is dedicated to finding better treatments and cures for inheritable bleeding disorders and to preventing the complications of these disorders through education, advocacy and research. The foundation was established in 1948 and has chapters throughout the country. Its programs and initiatives are made possible through the generosity of individuals, corporations and foundations as well as through a cooperative agreement with the Centers for Disease Control and Prevention (CDC).
The IHTC has a long history of collaborating with and supporting NBDF. Dr. Amy Shapiro, co-founder, CEO and Co-Medical Director of IHTC, served for many years as a member of the foundation’s Medical and Scientific Advisory Council (MASAC). MASAC is composed of physicians, scientists and other medical professionals with a wide range of expertise on bleeding disorders, blood safety and infectious disease.
IHTC collaborates with NBDF to promote ongoing training for HTC clinical staff across the country. These efforts include the Partners in Bleeding Program which is a national program originally established by IHTC. The Partners program offers multiple live training sessions at basic and advanced levels as well as online learning modules. IHTC also provides financial support for NBDF’s social work and physical working groups.
Hemophilia of Michigan
The Hemophilia Foundation of Michigan (HFM) was founded in 1956 and began as an all-volunteer chapter of the National Hemophilia Foundation (now the National Bleeding Disorders Foundation). In 1984, HFM was appointed by the Maternal and Child Health Bureau as the federal Regional Core Center for Michigan, Ohio, and Indiana Comprehensive Hemophilia Treatment Centers (HTCs).
IHTC staff serve as members of HFM’s Regional Advisory Council which provides input to HFM in its role as the Regional Core Center. IHTC also provides support for HFM programs that advance education for HTC clinical staff and patients in the region. These programs include the annual Regional Meeting for HTC staff and new education programs for patients such as HFM’s Women’s Conference.
Partners
The IHTC founded the Partners in Bleeding Disorders Education (“Partners”) Program in 1996. The Partners in Bleeding Disorders Education Program promotes excellence in care through education created by and for the federally recognized Hemophilia Treatment Center (HTC) Network and providers from a variety of disciplines that serve patients with bleeding and other coagulation disorders. Programs include Basic Partners, Advanced Partners, Specialty Workshops, PartnersPRN online learning activities, and Partners Physician Academy. The Partners in Bleeding Disorders Education programs offer comprehensive education, both in person and online, for Hemophilia Treatment Center (HTC) staff including disciplines such as nursing, physical therapy, and social work. We also provide accredited open access learning activities for non-HTC physicians and nurses who care for persons with bleeding and/or clotting disorders in their practice.
Physician Academy
In 2021, the IHTC—with generous support and collaboration from the Hemophilia Alliance and The Alliance Pharmacy—initiated the development of the Partners Physician Academy as a US-based bleeding disorders-focused education program delivered by hematology experts. The program’s goal is to support and accelerate career advancement of physicians in fellowship or those early in their career, for leadership as part of the Hemophilia Treatment Center (HTC) network. The Partners Physician Academy is a 5-day training course held in Indianapolis, IN. This innovative program deepens the commitment of participants to the bleeding disorder community by development new, collaborative opportunities to support continued mentorship throughout their careers, with the goal of advancing patient care.
International Partnerships
World Federation of Hemophilia
For more than 50 years, the World Federation of Hemophilia (WFH) has provided global leadership to improve and sustain care for people with inherited bleeding disorders, including hemophilia, von Willebrand disease, rare factor deficiencies, and inherited platelet disorders. The IHTC has participated in the WFH’s Twinning Program, which supplemented IHTC’s early efforts to establish a Hemophilia Treatment Center in western Kenya. IHTC’s partners in Kenya continue to participate in the WFH Humanitarian Aid Program which provides donated clotting factor concentrate to patients in need, as well as a laboratory quality assurance program to ensure the lab in Kenya is able to provide high-quality laboratory results to clinicians and patients.